-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Arcellx, Inc. (NASDAQ:ACLX) Major Shareholder Scott D. Sandell Sells 390 Shares
Arcellx, Inc. (NASDAQ:ACLX) Major Shareholder Scott D. Sandell Sells 390 Shares
Arcellx, Inc. (NASDAQ:ACLX – Get Rating) major shareholder Scott D. Sandell sold 390 shares of Arcellx stock in a transaction on Friday, December 23rd. The shares were sold at an average price of $31.67, for a total value of $12,351.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Arcellx Trading Down 5.8 %
Arcellx stock traded down $1.82 during mid-day trading on Tuesday, hitting $29.62. The company's stock had a trading volume of 336,656 shares, compared to its average volume of 386,509. The company has a current ratio of 6.48, a quick ratio of 6.48 and a debt-to-equity ratio of 0.11. The stock's fifty day moving average is $23.56 and its two-hundred day moving average is $20.49. Arcellx, Inc. has a 1 year low of $6.03 and a 1 year high of $33.99. The firm has a market capitalization of $1.30 billion and a PE ratio of -0.67.
Get Arcellx alerts:Wall Street Analyst Weigh In
ACLX has been the topic of several research analyst reports. Canaccord Genuity Group boosted their price target on Arcellx from $32.00 to $34.00 in a research note on Monday, December 12th. SVB Leerink reduced their target price on Arcellx to $35.00 in a report on Thursday, November 24th. Piper Sandler increased their target price on Arcellx from $96.00 to $104.00 in a report on Friday, December 9th. Guggenheim started coverage on Arcellx in a research report on Monday, October 31st. They issued a "buy" rating and a $36.00 price target for the company. Finally, Needham & Company LLC upped their price target on Arcellx from $31.00 to $35.00 and gave the company a "buy" rating in a research report on Monday, December 12th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $43.88.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the company. Novo Holdings A S acquired a new position in Arcellx during the first quarter worth $56,317,000. Cormorant Asset Management LP raised its stake in shares of Arcellx by 99.9% in the third quarter. Cormorant Asset Management LP now owns 3,049,173 shares of the company's stock valued at $57,233,000 after acquiring an additional 1,524,173 shares in the last quarter. Perceptive Advisors LLC raised its stake in shares of Arcellx by 115.9% in the third quarter. Perceptive Advisors LLC now owns 2,465,405 shares of the company's stock valued at $46,276,000 after acquiring an additional 1,323,415 shares in the last quarter. BlackRock Inc. raised its stake in shares of Arcellx by 199.8% in the third quarter. BlackRock Inc. now owns 1,806,103 shares of the company's stock valued at $33,902,000 after acquiring an additional 1,203,592 shares in the last quarter. Finally, Citadel Advisors LLC raised its stake in shares of Arcellx by 34.1% in the second quarter. Citadel Advisors LLC now owns 1,769,400 shares of the company's stock valued at $31,333,000 after acquiring an additional 450,374 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.About Arcellx
(Get Rating)
Arcellx, Inc, a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).
Featured Stories
- Get a free copy of the StockNews.com research report on Arcellx (ACLX)
- The Institutions Choose CarMax Over Carvana, Should You?
- Heatmap in Trading: How to Learn What Market Depth Hides
- Micron Technology Sees Chip Recovery by the End of 2023
- Three Healthcare Penny Stocks to Watch In The New Year
- Southwest Airlines Stock, There is a Lot to Love
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.
Arcellx, Inc. (NASDAQ:ACLX – Get Rating) major shareholder Scott D. Sandell sold 390 shares of Arcellx stock in a transaction on Friday, December 23rd. The shares were sold at an average price of $31.67, for a total value of $12,351.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
阿塞爾克斯公司（NASDAQ：ACLX-獲得評級）主要股東斯科特·桑德爾在 12 月 23 日（星期五）的一項交易中出售了 390 股阿塞爾克斯股票。這些股票以 31 美元的平均價格出售，總價值為 12,351.30 美元。該銷售在與證券交易委員會的法律文件中披露，該文件可在以下位置獲得 此超連結。擁有公司股票至少 10% 的主要股東必須向 SEC 披露其交易。
Arcellx Trading Down 5.8 %
阿塞爾克斯交易下跌 5.8%
Arcellx stock traded down $1.82 during mid-day trading on Tuesday, hitting $29.62. The company's stock had a trading volume of 336,656 shares, compared to its average volume of 386,509. The company has a current ratio of 6.48, a quick ratio of 6.48 and a debt-to-equity ratio of 0.11. The stock's fifty day moving average is $23.56 and its two-hundred day moving average is $20.49. Arcellx, Inc. has a 1 year low of $6.03 and a 1 year high of $33.99. The firm has a market capitalization of $1.30 billion and a PE ratio of -0.67.
阿塞爾克斯股票在周二中間交易期間下跌了 1.82 美元，觸及 29.62 美元。該公司的股票交易量為 336,656 股，而其平均交易量為 386,509。該公司的流動比率為 6.48，快速比率為 6.48，債務與權益比率為 0.11。股票的五十天移動平均線為 23.56 美元，其 200 日移動平均線為 20.49 美元。阿塞爾克斯公司擁有 1 年低點 6.03 美元，創下 1 年最高點 33.99 美元。該公司的市值為 130 億美元，私募股權比率為 -0.67。
Wall Street Analyst Weigh In
華爾街分析師稱重
ACLX has been the topic of several research analyst reports. Canaccord Genuity Group boosted their price target on Arcellx from $32.00 to $34.00 in a research note on Monday, December 12th. SVB Leerink reduced their target price on Arcellx to $35.00 in a report on Thursday, November 24th. Piper Sandler increased their target price on Arcellx from $96.00 to $104.00 in a report on Friday, December 9th. Guggenheim started coverage on Arcellx in a research report on Monday, October 31st. They issued a "buy" rating and a $36.00 price target for the company. Finally, Needham & Company LLC upped their price target on Arcellx from $31.00 to $35.00 and gave the company a "buy" rating in a research report on Monday, December 12th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $43.88.
ACLX 一直是幾個研究分析師報告的主題。康雅克真誠集團在 12 月 12 日星期一的一份研究報告中，將阿塞爾克斯的價格目標從 32.00 美元提高到 34.00 美元。在 11 月 24 日（星期四）的一份報告中，SVB 萊林克斯將其在阿塞爾克斯的目標價格下調至 35.00 美元。派珀桑德勒在 12 月 9 日（星期五）的一份報告中，將阿塞爾克斯的目標價格從 96.00 美元提高到 104.00 美元。古根海姆在 10 月 31 日星期一的研究報告中開始對阿塞爾克斯進行報導。他們為該公司發布了「購買」評級和 36.00 美元的目標價格。最後，李約翰公司有限責任公司將其對 Arcellx 的目標價格從 31.00 美元提高至 35.00 美元，並在 12 月 12 日週一的研究報告中給該公司「買入」評級。八位投資分析師對該股票進行了買入評級，根據 MarketBeat.com 的數據，該公司的平均評級為「買入」，共識目標價格為 43.88 美元。
Institutional Inflows and Outflows
機構流入和流出
About Arcellx
關於阿賽克斯
(Get Rating)
(取得評分)
Arcellx, Inc, a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).
Arcellx, Inc 是一家臨床階段的生物技術公司，致力於為癌症和其他不治之疾病患者開發各種免疫療法。該公司的主導 DDCar 產品候選產品是 CART-DDBCMA，該臨床試驗正在用於治療復發或難治（r/r）多發性骨髓瘤（MM）患者的一期臨床試驗中。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Arcellx (ACLX)
- The Institutions Choose CarMax Over Carvana, Should You?
- Heatmap in Trading: How to Learn What Market Depth Hides
- Micron Technology Sees Chip Recovery by the End of 2023
- Three Healthcare Penny Stocks to Watch In The New Year
- Southwest Airlines Stock, There is a Lot to Love
- 獲取有關阿塞爾克斯（ACLX）的研究報告的免費副本
- 機構選擇 CarMax 而不是卡瓦娜，你應該嗎？
- 交易中的熱圖：如何了解市場深度隱藏了什麼
- 美光技術將在 2023 年底前恢復芯片
- 三個醫療保健便士股在新的一年要關注
- 西南航空股票，有很多值得愛的地方
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.
接收阿塞勒克斯日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Arcellx 及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧